Loading...
Market
Human clinical trial of bridge RNA-guided DNA recombination by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
ClinicalTrials.gov or official press releases from Arc Institute
Story
Arc Institute's Bridge RNA-Guided DNA Recombination Published in Nature for Precise Genome Editing
Jun 26, 2024, 04:20 PM
Researchers from the Arc Institute have introduced a groundbreaking genome engineering technology known as bridge RNA-guided DNA recombination. This new mechanism, detailed in two papers published in Nature, allows for the programmable insertion, excision, or inversion of DNA sequences. Unlike CRISPR, bridge RNA-guided DNA recombination does not rely on cellular repair mechanisms, potentially making it safer and more precise. The discovery includes three atomic structures of the first natural RNA-guided recombinase, which enhances the power and precision of genome editing for long DNA sequences. This modular system involves the IS110 recombinase and non-coding RNA, significantly reshaping animal and plant genomes.
View original story
Similar markets
Yes • 50%
No • 50%
Gene therapy • 33%
Agricultural biotechnology • 33%
Synthetic biology • 33%
FDA (US) • 25%
EMA (Europe) • 25%
NMPA (China) • 25%
Other • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
No clinical trials • 25%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
NTLA-2002 • 25%
Editas Medicine Therapy • 25%
Beam Therapeutics Therapy • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Human gene editing • 25%
Animal models • 25%
Plant genomics • 25%
Microbial engineering • 25%
